Showing 5331-5340 of 5643 results for "".
- Eyecare Services Partners Names New CEO and Adds Two Other Executiveshttps://modernod.com/news/eyecare-services-partners-names-new-ceo-and-adds-two-other-executives/2476353/Eyecare Services Partners (ESP) has appointed George Neal as chief executive officer, effective March 4. Mr. Neal was previously chief executive officer of Access Dental, a dental services organization that was recently sold by Guardian Life Insurance Company of America, according to a
- New Laser Helps Doctors Image Full Eye in 3Dhttps://modernod.com/news/new-laser-helps-doctors-image-full-eye-in-3d/2476348/Scientists have developed a laser-based technique that can produce a full 3D image of all the layers of the retina, allowing doctors to better diagnose and treat eye diseases such as cataracts, diabetic retinopathy, and cancer, according to an Octlight news release. Researchers from the Te
- Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophyhttps://modernod.com/news/apellis-resumes-dosing-in-its-phase-3-program-for-patients-with-geographic-atrophy/2479589/Apellis Pharmaceuticals announced that it has resumed enrollment in its two phase 3 GA trials (DERBY & OAKS) with intravitreal APL-2 for the treatment of geographic atrophy (GA). In October 2018, Apellis
- Aldeyra Therapeutics Provides Update on Ophthalmic Programshttps://modernod.com/news/aldeyra-therapeutics-provides-update-on-ophthalmic-programs/2476256/Aldeyra Therapeutics updated progress on ophthalmic programs at a 2019 Research & Development Day in New York City. Presentations were given by members of the Aldeyra executive team along with Dean Eliott, MD, the Stelios Evangel
- TopiVert Announces First Patients Dosed in THEIA-1 Phase 2b/3 Study of Dry Eye Disease Treatmenthttps://modernod.com/news/topivert-announces-first-patients-dosed-in-theia-1-phase-2b-3-study-of-dry-eye-disease-treatment/2476259/TopiVert Pharma announced that the first patients have been dosed in the THEIA-1 phase 2b/3 clinical study evaluating TOP1630, a novel anti-inflammatory kinase inhibitor, as an ophthalmic solution for the treatment of dry eye disease. THEIA-1 is a multicenter, randomised, double-masked, pl
- Nidek Launches Upgraded AngioScan OCT-Angiography Softwarehttps://modernod.com/news/nidek-launches-upgraded-angioscan-oct-angiography-software/2476265/Nidek has announced the launch of new AngioScan upgraded OCT-Angiography software that enables visualization of retinal and choroidal microvasculature and blood flow using the RS-3000 Advance 2 OCT device. The
- FDA Approves Bausch + Lomb’s Lotemax SM For The Treatment Of Postoperative Inflammation And Painhttps://modernod.com/news/fda-approves-bausch-lombs-lotemax-sm-for-the-treatment-of-postoperative-inflammation-and-pain/2476267/Bausch + Lomb announced that the FDA has approved Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, a new gel formulation for the treatment of postoperative inflammation and pain following ocular surgery. Compared to Lotemax Gel 0.5%, Lotemax SM delivers a submicron particle size for faste
- Ocular Therapeutix Announces Dosing of First Patient in Phase 1 Clinical Trial for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-dosing-of-first-patient-in-phase-1-clinical-trial-for-the-treatment-of-wet-amd/2476273/Ocular Therapeutix announced the dosing of the first patient in a phase 1 trial of OTX-TKI (tyrosine kinase inhibitor implant) in patients with wet age-related macular degeneration (AMD). The first patient was dosed at the Sydney Retina Clinic in Sydney, Australia. “We are excited to annou
- ReNeuron Group Announces Positive Preliminary Data in US Retinitis Pigmentosa Trialhttps://modernod.com/news/reneuron-group-announces-positive-preliminary-data-in-us-retinitis-pigmentosa-trial/2476276/ReNeuron Group announced positive preliminary results in the company’s ongoing phase 1/2 clinical trial of its human retinal progenitor cells (hRPC) cell therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2 part of the trial have demonstrate
- New Medscape Report Finds More Than One in Three Doctors are Burned Outhttps://modernod.com/news/new-medscape-report-finds-more-than-one-in-three-doctors-are-burned-out/2476292/Burnout and depression are having a significant effect on the global medical community, as demonstrated by Medscape’s Global Physicians’ Burnout and Lifestyle Comparisons report. Nearly 20,000 doctors in six countries (France,